Due to the fact that Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has faced declining sentiment from the entirety of the hedge funds we track, it’s safe to say that there was a specific group of hedgies that decided to sell off their entire …
That creates more demand for the stock, which pushes it higher, which forces more shorts to buy the shares and so on and so on. Look at Ligand Pharmaceuticals Inc. (NASDAQ:LGND). The stock has had a big run this year, especially …
SmarTrend identified an Uptrend for Ligand Pharm (NASDAQ:LGND) on March 10th, 2017 at $108.63. In approximately 5 months, Ligand Pharm has returned 16.88% as of today's recent price of $126.97. Over the past year, Ligand Pharm …
Ligand Pharmaceuticals Inc. (LGND) ended long rallies around the $120 level in 1996, 2000, 2002 and 2004 so it wasn’t a surprise when the most recent uptick ran into a buzzsaw of selling pressure after the stock traded above the magic …
LGND data by YCharts. While I'm cherry-picking the data to make ... Last year, the millionaire-maker stock generated $71.9 million in total revenue, representing growth of 11% from 2014 and 129% growth from 2012. The unique business …
12:01a Peru economy to grow by more than 3 pct in 4th qtr -finmin - Nasdaq 09/12 $GBDC Stock Quote Alert for Golub …
Trade what you see, not what you believe. The strength in the averages and leaders may ... Among the names, Ligand Pharmaceuticals LGND, +0.05% is a rare leader that sets up in a base, this one of five weeks. The developer of drugs …
Nov 21, 2016 07:30 AM Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016 Nov 21, 2016 06:42 AM Roth Capital …
Halozyme Therapeutics (HALO): Barclays trims the stock to Equal Weight from Overweight. Ligand Pharmaceuticals (LGND): LGND is lowered to Sell from Hold at Cantor Fitzgerald due to valuation. Its amended price objective is $37. …
Click to get this free report SPECTRUM PHARMA (NASDAQ: SPPI): Free Stock Analysis Report ARIAD PHARMA (NASDAQ: ARIA): Free Stock Analysis Report LIGAND PHARMA-B (NASDAQ: LGND): Free Stock Analysis Report